CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Protagonist Therapeutics, Inc. - PTGX CFD

28.85
1.62%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.09
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Protagonist Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 28.41
Open* 28.09
1-Year Change* 29.33%
Day's Range* 28.09 - 29.13
52 wk Range 11.21-30.10
Average Volume (10 days) 899.55K
Average Volume (3 months) 14.98M
Market Cap 1.38B
P/E Ratio -100.00K
Shares Outstanding 57.68M
Revenue N/A
EPS -2.61
Dividend (Yield %) N/A
Beta 2.01
Next Earnings Date Mar 13, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 28.87 1.02 3.66% 27.85 29.21 27.48
Mar 27, 2024 28.41 0.33 1.18% 28.08 28.56 27.90
Mar 26, 2024 27.94 0.02 0.07% 27.92 28.27 27.52
Mar 25, 2024 27.83 -0.05 -0.18% 27.88 28.38 27.58
Mar 22, 2024 27.97 -0.18 -0.64% 28.15 28.29 27.78
Mar 21, 2024 28.33 -0.61 -2.11% 28.94 29.57 28.22
Mar 20, 2024 28.85 0.31 1.09% 28.54 28.91 27.93
Mar 19, 2024 28.77 0.77 2.75% 28.00 28.89 28.00
Mar 18, 2024 28.42 -0.27 -0.94% 28.69 29.06 28.19
Mar 15, 2024 28.96 0.80 2.84% 28.16 29.91 28.16
Mar 14, 2024 28.30 -1.14 -3.87% 29.44 29.72 28.13
Mar 13, 2024 30.17 0.33 1.11% 29.84 30.51 29.34
Mar 12, 2024 29.85 0.16 0.54% 29.69 30.21 29.45
Mar 11, 2024 30.08 0.11 0.37% 29.97 30.67 29.70
Mar 8, 2024 30.27 -0.60 -1.94% 30.87 31.44 30.15
Mar 7, 2024 30.83 -0.43 -1.38% 31.26 31.51 30.79
Mar 6, 2024 31.23 0.36 1.17% 30.87 31.35 30.49
Mar 5, 2024 30.88 -0.53 -1.69% 31.41 31.66 30.73
Mar 4, 2024 31.61 -0.53 -1.65% 32.14 32.29 31.10
Mar 1, 2024 32.08 1.71 5.63% 30.37 33.22 30.37

Protagonist Therapeutics, Inc. Events

Time (UTC) Country Event
Thursday, May 2, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Protagonist Therapeutics Inc Earnings Release
Q1 2024 Protagonist Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Friday, May 24, 2024

Time (UTC)

17:00

Country

US

Event

Protagonist Therapeutics Inc Annual Shareholders Meeting
Protagonist Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 26.581 27.357 28.628 0.231 30.925
Total Operating Expense 157.954 153.202 93.729 80.752 73.194
Selling/General/Admin. Expenses, Total 31.739 27.196 18.638 15.749 13.697
Research & Development 126.215 126.006 74.506 65.003 59.497
Operating Income -131.373 -125.845 -65.101 -80.521 -42.269
Interest Income (Expense), Net Non-Operating 4.06 0.443 0.302 2.644 2.546
Other, Net -0.08 -0.149 -0.046 -0.001 0
Net Income Before Taxes -127.393 -125.551 -64.845 -77.878 -39.723
Net Income After Taxes -127.393 -125.551 -66.15 -77.187 -38.924
Net Income Before Extra. Items -127.393 -125.551 -66.15 -77.187 -38.924
Net Income -127.393 -125.551 -66.15 -77.187 -38.924
Total Adjustments to Net Income 0
Income Available to Common Excl. Extra. Items -127.393 -125.551 -66.15 -77.187 -38.924
Income Available to Common Incl. Extra. Items -127.393 -125.551 -66.15 -77.187 -38.924
Diluted Net Income -127.393 -125.551 -66.15 -77.187 -38.924
Diluted Weighted Average Shares 49.0422 46.3229 34.3965 25.894 22.3645
Diluted EPS Excluding Extraordinary Items -2.59762 -2.71034 -1.92316 -2.98088 -1.74044
Diluted Normalized EPS -2.59762 -2.71034 -1.91211 -2.98088 -1.74044
Revenue 26.581 27.357 28.628 0.231 30.925
Total Extraordinary Items
Dividends per Share - Common Stock Primary Issue 0
Unusual Expense (Income) 0 0 0.585
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0.859
Revenue 0 0 0 0 0.859
Total Operating Expense 42.354 36.021 36.516 32.303 42.302
Selling/General/Admin. Expenses, Total 9.172 8.605 6.632 6.901 7.691
Research & Development 33.182 27.416 29.884 25.402 34.611
Operating Income -42.354 -36.021 -36.516 -32.303 -41.443
Interest Income (Expense), Net Non-Operating 3.913 2.491 2.251 1.157 0.484
Other, Net -0.019 -0.195 0.071 -0.086 -0.078
Net Income Before Taxes -38.46 -33.725 -34.194 -31.232 -41.037
Net Income After Taxes -38.46 -33.725 -34.194 -31.232 -41.037
Net Income Before Extra. Items -38.46 -33.725 -34.194 -31.232 -41.037
Net Income -38.46 -33.725 -34.194 -31.232 -41.037
Income Available to Common Excl. Extra. Items -38.46 -33.725 -34.194 -31.232 -41.037
Income Available to Common Incl. Extra. Items -38.46 -33.725 -34.194 -31.232 -41.037
Diluted Net Income -38.46 -33.725 -34.194 -31.232 -41.037
Diluted Weighted Average Shares 56.7757 50.5737 49.2549 49.1076 49.0499
Diluted EPS Excluding Extraordinary Items -0.6774 -0.66685 -0.69422 -0.63599 -0.83664
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.6774 -0.66685 -0.69422 -0.63599 -0.83664
Unusual Expense (Income) 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 243.077 340.736 315.606 145.311 137.503
Cash and Short Term Investments 237.355 326.9 305.809 133.017 128.853
Cash & Equivalents 125.744 123.665 117.358 33.006 82.233
Short Term Investments 111.611 203.235 188.451 100.011 46.62
Total Receivables, Net 0.052 5.333 3.821 7.499 6.511
Prepaid Expenses 5.67 8.503 5.966 4.785 2.129
Other Current Assets, Total 0.01 0.01 0.01
Total Assets 247.928 347.695 324.468 154.917 139.472
Property/Plant/Equipment, Total - Net 4.626 6.734 6.412 7.723 0.861
Property/Plant/Equipment, Total - Gross 9.88 10.992 9.885 10.364 2.938
Accumulated Depreciation, Total -5.254 -4.258 -3.473 -2.641 -2.077
Long Term Investments 2
Other Long Term Assets, Total 0.225 0.225 0.45 1.883 1.108
Total Current Liabilities 31.179 44.016 40.241 35.406 26.158
Accounts Payable 3.64 1.6 3.075 2.79 5.711
Payable/Accrued
Accrued Expenses 27.055 39.509 19.875 13.494 11.068
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 32.32 47.674 44.862 74.953 26.957
Total Long Term Debt 0 0 0 9.794 0
Long Term Debt 0 9.794
Total Equity 215.608 300.021 279.606 79.964 112.515
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.00049 0.00048 0.00044 0.00027 0
Additional Paid-In Capital 752.722 709.682 563.389 297.846 253.222
Retained Earnings (Accumulated Deficit) -536.755 -409.362 -283.811 -217.661 -140.474
Other Equity, Total -0.35949 -0.29948 0.02756 -0.22127 -0.233
Total Liabilities & Shareholders’ Equity 247.928 347.695 324.468 154.917 139.472
Total Common Shares Outstanding 49.3392 47.8383 43.7455 27.2176 23.1872
Other Current Liabilities, Total 0.484 2.907 17.291 19.122 9.379
Other Liabilities, Total 1.141 3.658 4.621 29.753 0.799
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 324.881 316.941 235.736 243.077 276.617
Cash and Short Term Investments 320.751 313.401 230.759 237.355 267.437
Cash & Equivalents 230.527 235.382 127.686 125.744 152.816
Short Term Investments 90.224 78.019 103.073 111.611 114.621
Total Receivables, Net 0.065 0.05 0.051 0.052 0.62
Prepaid Expenses 4.065 3.49 4.926 5.67 8.56
Total Assets 330.016 320.466 239.858 247.928 282.174
Property/Plant/Equipment, Total - Net 2.925 3.3 3.897 4.626 5.332
Long Term Investments 1.985
Other Long Term Assets, Total 0.225 0.225 0.225 0.225 0.225
Total Current Liabilities 27.867 26.398 23.229 31.179 36.754
Accounts Payable 1.252 4.573 4.021 3.64 4.715
Accrued Expenses 26.468 21.65 18.852 27.055 31.816
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.147 0.175 0.356 0.484 0.223
Total Liabilities 27.867 26.398 23.691 32.32 38.558
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0 0 0.462 1.141 1.804
Total Equity 302.149 294.068 216.167 215.608 243.616
Common Stock 0.001 0.001 0.001 0.00049 0.00049
Additional Paid-In Capital 945.363 903.205 786.768 752.722 746.657
Retained Earnings (Accumulated Deficit) -643.045 -608.94 -570.48 -536.755 -502.561
Other Equity, Total -0.17 -0.198 -0.122 -0.35949 -0.48049
Total Liabilities & Shareholders’ Equity 330.016 320.466 239.858 247.928 282.174
Total Common Shares Outstanding 57.6475 57.4942 51.4405 49.3392 49.1984
Other Current Assets, Total
Redeemable Preferred Stock 0 0 0 0 0
Property/Plant/Equipment, Total - Gross 8.871 9.021 9.389 9.88 10.302
Accumulated Depreciation, Total -5.946 -5.721 -5.492 -5.254 -4.97
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -127.393 -125.551 -66.15 -77.187 -38.924
Cash From Operating Activities -108.137 -107.865 -72.484 -41.527 -49.947
Cash From Operating Activities 1.034 0.813 0.789 0.703 0.527
Non-Cash Items 25.988 20.187 10.455 9.588 7.125
Changes in Working Capital -7.766 -3.314 -19.016 26.144 -18.017
Cash From Investing Activities 91.468 -15.86 -90.965 -53.71 2.213
Capital Expenditures -0.795 -1.101 -0.471 -0.967 -0.486
Other Investing Cash Flow Items, Total 92.263 -14.759 -90.494 -52.743 2.699
Cash From Financing Activities 18.838 129.923 247.626 46.036 24.115
Issuance (Retirement) of Stock, Net 19.001 130.112 258.164 36.271 24.115
Foreign Exchange Effects -0.09 -0.126 0.175 -0.026 -0.177
Net Change in Cash 2.079 6.072 84.352 -49.227 -23.796
Deferred Taxes 0 1.438 -0.775 -0.658
Cash Taxes Paid 0 0 0.438 0.07
Issuance (Retirement) of Debt, Net 0 -10.524 9.765
Financing Cash Flow Items -0.163 -0.189 -0.014
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -33.725 -127.393 -93.199 -61.967 -20.93
Cash From Operating Activities -34.347 -108.137 -76.502 -51.301 -37.666
Cash From Operating Activities 0.248 1.034 0.778 0.508 0.249
Non-Cash Items 7.107 25.988 20.806 14.362 6.877
Changes in Working Capital -7.977 -7.766 -4.887 -4.204 -23.862
Cash From Investing Activities 9.826 91.468 87.533 30.258 -4.476
Capital Expenditures -0.01 -0.795 -0.725 -0.563 -0.273
Other Investing Cash Flow Items, Total 9.836 92.263 88.258 30.821 -4.203
Cash From Financing Activities 26.463 18.838 18.285 17.605 16.925
Financing Cash Flow Items -0.1 -0.163 -0.163 -0.161 -0.186
Issuance (Retirement) of Stock, Net 26.563 19.001 18.448 17.766 17.111
Foreign Exchange Effects 0 -0.09 -0.165 0.01 0.029
Net Change in Cash 1.942 2.079 29.151 -3.428 -25.188
Deferred Taxes 0
Issuance (Retirement) of Debt, Net 0
Cash Taxes Paid 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Protagonist Therapeutics, Inc. Company profile

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs fall under two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. Its other clinical assets PTG-943 and PTG-200, are orally delivered investigational drugs in development for inflammatory bowel disease (IBD) that are designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-235 and PN-232 are in clinical development, which are IL-R antagonists. Protagonist Pty Limited is its subsidiary.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Protagonist Therapeutics Inc revenues decreased 4% to $27.4M. Net loss increased 90% to $125.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 66% to $117M (expense), General and administrative - Balancin increase of 33% to $19.8M (expense).

Industry: Biotechnology & Medical Research (NEC)

7707 Gateway Blvd Ste 140
NEWARK
CALIFORNIA 94560-1160
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

XRP/USD

0.63 Price
-1.610% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

70,500.80 Price
-0.520% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,570.17 Price
+0.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading